Genome-scale search of tumor-specific antigens by collective analysis of mutations, expressions and T-cell recognition

Molecular Immunology

Volumn 46, Issue 8-9, 2009, Pages 1824-1829

  Jia, Jia ^a   Cui, Juan ^b   Liu, Xianghui ^a   Han, Jinhua ^c   Yang, Shengyong ^d   Wei, Yuquan ^d   Chen, Yuzong ^a,d  

^a Bioinformatics and Drug Design Group   (Singapore)

^b University of Georgia   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d SICHUAN UNIVERSITY   (China)

Author keywords

Cancer vaccines; Human cancer genomes; Tumor specific antigens

Indexed keywords

EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELANOMA ANTIGEN; TUMOR ANTIGEN;

ARTICLE; CANCER GENETICS; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; IMMUNE RESPONSE; LUNG CANCER; MELANOMA; MOLECULAR RECOGNITION; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR IMMUNITY;

ALLELES; AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; CHROMOSOME MAPPING; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HLA ANTIGENS; HUMANS; LUNG NEOPLASMS; MELANOMA; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES;

EID: 64149120251     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2009.01.019     Document Type: Article

References (55)

1. Adam J.K., Odhav B., and Bhoola K.D. Immune responses in cancer. Pharmacol. Ther. 99 (2003) 113-132
2. Aladin F., Lautscham G., Humphries E., Coulson J., and Blake N. Targeting tumour cells with defects in the MHC Class I antigen processing pathway with CD8+ T cells specific for hydrophobic TAP- and tapasin-independent peptides: the requirement for directed access into the ER. Cancer Immunol. Immunother. 56 (2007) 1143-1152
3. Alimonti J., Zhang Q.J., Gabathuler R., Reid G., Chen S.S., and Jefferies W.A. TAP expression provides a general method for improving the recognition of malignant cells in vivo. Nat. Biotechnol. 18 (2000) 515-520
4. Atkins D., Ferrone S., Schmahl G.E., Storkel S., and Seliger B. Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma?. J. Urol. 171 (2004) 885-889
5. Bamford S., Dawson E., Forbes S., Clements J., Pettett R., Dogan A., Flanagan A., Teague J., Futreal P.A., Stratton M.R., and Wooster R. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br. J. Cancer 91 (2004) 355-358
6. Bian H., and Hammer J. Discovery of promiscuous HLA-II-restricted T cell epitopes with TEPITOPE. Methods 34 (2004) 468-475
7. Cui J., Han L.Y., Lin H.H., Zhang H.L., Tang Z.Q., Zheng C.J., Cao Z.W., and Chen Y.Z. Prediction of MHC-binding peptides of flexible lengths from sequence-derived structural and physicochemical properties. Mol. Immunol. 44 (2007) 866-877
8. Donnes P., and Kohlbacher O. Integrated modeling of the major events in the MHC class I antigen processing pathway. Protein Sci. 14 (2005) 2132-2140
9. Doytchinova I.A., Walshe V.A., Jones N.A., Gloster S.E., Borrow P., and Flower D.R. Coupling in silico and in vitro analysis of peptide-MHC binding: a bioinformatic approach enabling prediction of superbinding peptides and anchorless epitopes. J. Immunol. 172 (2004) 7495-7502
10. Dunn G.P., Old L.J., and Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21 (2004) 137-148
11. Edgar R., Domrachev M., and Lash A.E. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30 (2002) 207-210
12. Ein-Dor L., Zuk O., and Domany E. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 5923-5928
13. Eisenbach L., Bar-Haim E., and El-Shami K. Antitumor vaccination using peptide based vaccines. Immunol Lett. 74 (2000) 27-34
14. Finn O.J. Cancer vaccines: between the idea and the reality. Nat. Rev. Immunol. 3 (2003) 630-641
15. Francis T. Mechanisms of Tumor Escape from the Immune Response (2003), Routledge, USA
16. Getz G., Hofling H., Mesirov J.P., Golub T.R., Meyerson M., Tibshirani R., and Lander E.S. Comment on "The consensus coding sequences of human breast and colorectal cancers". Science 317 (2007) 1500
17. Golub T.R., Slonim D.K., Tamayo P., Huard C., Gaasenbeek M., Mesirov J.P., Coller H., Loh M.L., Downing J.R., Caligiuri M.A., Bloomfield C.D., and Lander E.S. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286 (1999) 531-537
18. Greiner J., Ringhoffer M., Simikopinko O., Szmaragowska A., Huebsch S., Maurer U., Bergmann L., and Schmitt M. Simultaneous expression of different immunogenic antigens in acute myeloid leukemia. Exp. Hematol. 28 (2000) 1413-1422
19. Hicklin D.J., Marincola F.M., and Ferrone S. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol. Med. Today 5 (1999) 178-186
20. Honeyman M.C., Brusic V., Stone N.L., and Harrison L.C. Neural network-based prediction of candidate T-cell epitopes. Nat. Biotechnol. 16 (1998) 966-969
21. Khan J., Wei J.S., Ringner M., Saal L.H., Ladanyi M., Westermann F., Berthold F., Schwab M., Antonescu C.R., Peterson C., and Meltzer P.S. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat. Med. 7 (2001) 673-679
22. Khanna R. Tumour surveillance: missing peptides and MHC molecules. Immunol. Cell Biol. 76 (1998) 20-26
23. Larsen M.V., Lundegaard C., Lamberth K., Buus S., Brunak S., Lund O., and Nielsen M. An integrative approach to CTL epitope prediction: a combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions. Eur. J. Immunol. 35 (2005) 2295-2303
24. Lichtman A.K.A.A.H. Cellular and Molecular Immunology, Updated Edition (Book + Student Consult + Evolve) (2005), W.B. Saunders Company
25. Lollini P.L., Cavallo F., Nanni P., and Forni G. Vaccines for tumour prevention. Nat. Rev. Cancer 6 (2006) 204-216
26. Lopez-Albaitero A., Nayak J.V., Ogino T., Machandia A., Gooding W., DeLeo A.B., Ferrone S., and Ferris R.L. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J. Immunol. 176 (2006) 3402-3409
27. Lou Y., Basha G., Seipp R.P., Cai B., Chen S.S., Moise A.R., Jeffries A.P., Gopaul R.S., Vitalis T.Z., and Jefferies W.A. Combining the antigen processing components TAP and Tapasin elicits enhanced tumor-free survival. Clin. Cancer Res. 14 (2008) 1494-1501
28. Mallios R.R. Predicting class II MHC/peptide multi-level binding with an iterative stepwise discriminant analysis meta-algorithm. Bioinformatics 17 (2001) 942-948
29. Mittendorf E.A., Peoples G.E., and Singletary S.E. Breast cancer vaccines: promise for the future or pipe dream?. Cancer 110 (2007) 1677-1686
30. Muthusamy V., Hobbs C., Nogueira C., Cordon-Cardo C., McKee P.H., Chin L., and Bosenberg M.W. Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes Cancer 45 (2006) 447-454
31. Nielsen M., Lundegaard C., Lund O., and Kesmir C. The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. Immunogenetics 57 (2005) 33-41
32. Nielsen M., Lundegaard C., Worning P., Hvid C.S., Lamberth K., Buus S., Brunak S., and Lund O. Improved prediction of MHC class I and class II epitopes using a novel Gibbs sampling approach. Bioinformatics 20 (2004) 1388-1397
33. Ogino T., Bandoh N., Hayashi T., Miyokawa N., Harabuchi Y., and Ferrone S. Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients. Clin Cancer Res. 9 (2003) 4043-4051
34. Okamoto I., Pirker C., Bilban M., Berger W., Losert D., Marosi C., Haas O.A., Wolff K., and Pehamberger H. Seven novel and stable translocations associated with oncogenic gene expression in malignant melanoma. Neoplasia 7 (2005) 303-311
35. Pardoll D. Does the immune system see tumors as foreign or self?. Annu. Rev. Immunol. 21 (2003) 807-839
36. Pelte C., Cherepnev G., Wang Y., Schoenemann C., Volk H.D., and Kern F. Random screening of proteins for HLA-A*0201-binding nine-amino acid peptides is not sufficient for identifying CD8 T cell epitopes recognized in the context of HLA-A*0201. J. Immunol. 172 (2004) 6783-6789
37. Peters B., Bulik S., Tampe R., Van Endert P.M., and Holzhutter H.G. Identifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors. J. Immunol. 171 (2003) 1741-1749
38. Petrovsky N., and Brusic V. Virtual models of the HLA class I antigen processing pathway. Methods 34 (2004) 429-435
39. Purcell A.W., McCluskey J., and Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat. Rev. Drug Discov. 6 (2007) 404-414
40. Rubin A.F., and Green P. Comment on "The consensus coding sequences of human breast and colorectal cancers". Science 317 (2007) 1500
41. Saxova P., Buus S., Brunak S., and Kesmir C. Predicting proteasomal cleavage sites: a comparison of available methods. Int. Immunol. 15 (2003) 781-787
42. Schlom J., Arlen P.M., and Gulley J.L. Cancer vaccines: moving beyond current paradigms. Clin. Cancer Res. 13 (2007) 3776-3782
43. Seliger B., Atkins D., Bock M., Ritz U., Ferrone S., Huber C., and Storkel S. Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. Clin. Cancer Res. 9 (2003) 1721-1727
44. Seliger B., Maeurer M.J., and Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol. Today 21 (2000) 455-464
45. Sherritt M., Cooper L., Moss D.J., Kienzle N., Altman J., and Khanna R. Immunization with tumor-associated epitopes fused to an endoplasmic reticulum translocation signal sequence affords protection against tumors with down-regulated expression of MHC and peptide transporters. Int. Immunol. 13 (2001) 265-271
46. Singh S., Ross S.R., Acena M., Rowley D.A., and Schreiber H. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J. Exp. Med. 175 (1992) 139-146
47. Stecca B., Mas C., Clement V., Zbinden M., Correa R., Piguet V., Beermann F., and Ruiz I.A.A. Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 5895-5900
48. Tenzer S., Peters B., Bulik S., Schoor O., Lemmel C., Schatz M.M., Kloetzel P.M., Rammensee H.G., Schild H., and Holzhutter H.G. Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding. Cell Mol. Life Sci. 62 (2005) 1025-1037
49. Van den Eynde B.J., and van der Bruggen P. T cell defined tumor antigens. Curr. Opin. Immunol. 9 (1997) 684-693
50. van Hall T., Wolpert E.Z., van Veelen P., Laban S., van der Veer M., Roseboom M., Bres S., Grufman P., de Ru A., Meiring H., de Jong A., Franken K., Teixeira A., Valentijn R., Drijfhout J.W., Koning F., Camps M., Ossendorp F., Karre K., Ljunggren H.G., Melief C.J., and Offringa R. Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat. Med. 12 (2006) 417-424
51. Vertuani S., Triulzi C., Roos A.K., Charo J., Norell H., Lemonnier F., Pisa P., Seliger B., and Kiessling R. HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice. Cancer Immunol. Immunother. 58 (2009) 653-664
52. Viola A., and Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science 273 (1996) 104-106
53. Weir B.A., Woo M.S., Getz G., Perner S., Ding L., Beroukhim R., Lin W.M., Province M.A., Kraja A., Johnson L.A., Shah K., Sato M., Thomas R.K., Barletta J.A., Borecki I.B., Broderick S., Chang A.C., Chiang D.Y., Chirieac L.R., Cho J., Fujii Y., Gazdar A.F., Giordano T., Greulich H., Hanna M., Johnson B.E., Kris M.G., Lash A., Lin L., Lindeman N., Mardis E.R., McPherson J.D., Minna J.D., Morgan M.B., Nadel M., Orringer M.B., Osborne J.R., Ozenberger B., Ramos A.H., Robinson J., Roth J.A., Rusch V., Sasaki H., Shepherd F., Sougnez C., Spitz M.R., Tsao M.S., Twomey D., Verhaak R.G., Weinstock G.M., Wheeler D.A., Winckler W., Yoshizawa A., Yu S., Zakowski M.F., Zhang Q., Beer D.G., Wistuba I.I., Watson M.A., Garraway L.A., Ladanyi M., Travis W.D., Pao W., Rubin M.A., Gabriel S.B., Gibbs R.A., Varmus H.E., Wilson R.K., Lander E.S., and Meyerson M. Characterizing the cancer genome in lung adenocarcinoma. Nature 450 (2007) 893-898
54. Wood L.D., Parsons D.W., Jones S., Lin J., Sjoblom T., Leary R.J., Shen D., Boca S.M., Barber T., Ptak J., Silliman N., Szabo S., Dezso Z., Ustyanksky V., Nikolskaya T., Nikolsky Y., Karchin R., Wilson P.A., Kaminker J.S., Zhang Z., Croshaw R., Willis J., Dawson D., Shipitsin M., Willson J.K., Sukumar S., Polyak K., Park B.H., Pethiyagoda C.L., Pant P.V., Ballinger D.G., Sparks A.B., Hartigan J., Smith D.R., Suh E., Papadopoulos N., Buckhaults P., Markowitz S.D., Parmigiani G., Kinzler K.W., Velculescu V.E., and Vogelstein B. The genomic landscapes of human breast and colorectal cancers. Science 318 (2007) 1108-1113
55. Zitvogel L., Tesniere A., and Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 6 (2006) 715-727